文献速递中毒与环境急症重症综合管理与镇静镇痛

获得性高铁血红蛋白血症10年回顾性研究:致病因素、临床特征与结局

A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes.
PubMed 文献 · Clin Toxicol (Phila) · 2026-03-23
一句话结论泰国中毒中心10年数据显示,获得性高铁血红蛋白血症主要病因为氨苯砜(30.18%)和敌稗(27.22%),就诊时休克是唯一预后因素,死亡率11.24%。

该研究为泰国中毒中心2013—2022年169例获得性高铁血红蛋白血症的10年回顾性队列研究。主要致病因素为氨苯砜(30.18%)和敌稗(27.22%),19.53%病例未能确定具体氧化剂。88.76%患者住院,40.24%入住ICU,死亡率11.24%。多因素二元回归分析显示,就诊时休克是唯一预后因素,可能反映严重合并并发症而非高铁血红蛋白血症的直接效应。作者认为早期识别、及时复苏和积极处理系统性并发症对改善生存至关重要。

要点

  • 氨苯砜(30.18%)和敌稗(27.22%)是主要致病因素,19.53%病例未能确定具体氧化剂。
  • 169例中88.76%住院、40.24%入住ICU,并发症发生率29.59%(最常见脓毒症和肺炎),死亡率11.24%。
  • 多因素分析显示就诊时休克是唯一预后因素,作者认为其可能反映严重合并并发症而非高铁血红蛋白血症直接效应。
  • 中位高铁血红蛋白浓度11.50%,最高48.85%;31.36%接受亚甲蓝治疗(中位剂量1 mg/kg),43.20%输血,33.73%插管。

适用人群与场景

  • 泰国中毒中心2013—2022年识别的获得性高铁血红蛋白血症患者,纳入标准为高铁血红蛋白浓度>3%或具有特征性氧饱和度差且随后临床恢复。

诊断标准与关键阈值

  • 获得性高铁血红蛋白血症诊断依据:高铁血红蛋白浓度>3%,或具有特征性氧饱和度差且随后临床恢复。

处置流程与药物剂量

  • 治疗包括给氧(95.86%)、静脉输液(81.07%)、亚甲蓝(31.36%;中位剂量1 mg/kg)、输血(43.20%)和插管(33.73%)。
  • 作者认为早期识别、及时复苏和积极处理系统性并发症对改善生存率至关重要。

红旗征与不能漏的情况

  • 就诊时休克是唯一预后因素,作者认为其可能反映严重合并并发症而非高铁血红蛋白血症的直接效应,强调早期识别全身性疾病的重要性。

研究设计与关键结果

  • 10年回顾性队列研究,纳入169例获得性高铁血红蛋白血症患者(中位年龄43岁;59.17%男性)。
  • 主要致病因素为氨苯砜(30.18%)和敌稗(27.22%),其次为草药和食物相关因素;19.53%病例未能确定具体氧化剂。
  • 神经系统、心血管和血液系统表现分别占24.26%、33.73%和40.24%。
  • 中位和高铁血红蛋白最高浓度分别为11.50%和48.85%。
  • 88.76%患者住院,40.24%需入住ICU;并发症发生率29.59%,最常见为脓毒症和肺炎;死亡率11.24%。
  • 多因素二元回归分析显示,就诊时休克是唯一预后因素。

证据类型、等级与局限

  • 证据类型:10年回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为早期识别、及时复苏和积极处理系统性并发症对改善获得性高铁血红蛋白血症患者生存率至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acquired methemoglobinemia results from exposure to various oxidizing agents; however, data remain limited in Asia, including Thailand, where certain drugs and agricultural chemicals are widely used. Local epidemiologic data are essential for early recognition and clinical management.

METHODS: A 10-year retrospective cohort study of poison center - identified cases of acquired methemoglobinemia (2013-2022). Patients were included if they had a methemoglobinemia (concentration >3%) or a characteristic oxygen saturation gap with subsequent clinical recovery. Demographic, exposure, clinical, treatment, and outcome data were collected, and factors associated with mortality were analyzed using a multivariate binary regression model.

RESULTS: Among 169 patients (median age 43 years; 59.17% male), the leading causes were dapsone (30.18%) and propanil (27.22%), followed by herbal and food-related agents. In some patients (19.53%), the specific oxidizing agents could not be identified. Neurological, cardiovascular, and hematologic manifestations occurred in 24.26%, 33.73%, and 40.24% of cases, respectively. The median and highest methemoglobin concentrations were 11.50% and 48.85%. Most patients (88.76%) were hospitalized, with 40.24% requiring admission to the intensive care unit. Treatments included administering oxygen (95.86%), intravenous fluids (81.07%), and methylthioninium chloride (31.36%; median dose: 1 mg/kg), as well as blood transfusion (43.20%) and intubation (33.73%). Complications occurred in 29.59% of cases, most commonly sepsis and pneumonia. The mortality rate was 11.24%.

DISCUSSION: Mortality was driven not only by the severity of methemoglobinemia but also by systemic complications that occurred during hospitalization. Shock at presentation was the sole prognostic factor and likely reflected severe concurrent complications rather than a direct effect of methemoglobinemia, emphasizing the prognostic importance of early systemic illness. Early recognition, prompt resuscitation, and timely management of complications are essential for improving survival rates.

CONCLUSIONS: Acquired methemoglobinemia is most often caused by dapsone and propanil. Shock at presentation may prognosticate a fatal outcome. Early diagnosis, timely therapy, and aggressive management of systemic complications are required to improve the patients' clinical outcomes.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Tansuwannarat P, Bualerd P, Rittilert P, et al. A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes. Clin Toxicol (Phila). 2026. PMID: 41870143. doi:10.1080/15563650.2026.2631791

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。